Medtronic Q1 2027 Earnings Analysis
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
Medtronic Q1 2027 Earnings Analysis
-
Letto da:
-
Di:
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
WELCOME TO BETA FINCH — MEDTRONIC Q1 FY2027
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Medtronic's fiscal 2027 first quarter — and it's a big one.
JORDAN: Yeah, a lot to unpack here. Big beats, a couple of surprise M&A announcements, and a robotics story that's getting more interesting by the day.
ALEX: Before we jump in, quick note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
JORDAN: With that out of the way, let's get into the numbers, because they were strong.
ALEX: $9.8 billion in revenue, up 13.7% organically, adjusted EPS of $1.45 — both well ahead of what analysts were expecting. Now, a chunk of that growth came from an accounting quirk: fiscal 2027 is a 53-week year, and that extra week added about 670 basis points to growth this quarter.
JORDAN: Right, but even stripping that out, CFO Thierry Piéton said it was their strongest quarterly performance in nearly eight years, excluding COVID comparisons. So this wasn't just a calendar trick — the underlying business is actually accelerating.
ALEX: And it was broad-based. CEO Geoff Martha kept hammering that point — it's not one hot product carrying the quarter, it's basically every major business line pulling its weight.
JORDAN: The headline story, though, is Cardiac Ablation Solutions — CAS. That business grew 88% worldwide, 139% in the U.S. They crossed $2 billion in trailing twelve-month revenue, ahead of schedule. Their Sphere-9 catheter picked up nine points of U.S. market share this quarter alone.
ALEX: Nine points in one quarter is wild for medtech.
JORDAN: It really is. And they're guiding CAS to grow at 2.5 times the broader electrophysiology market for the full year — even upgraded that to more than 3x for Q2. The U.S. installed base for their Affera system grew 35% sequentially, on top of 40% the quarter before.
ALEX: Which tells you they're nowhere near saturated. Management said 75% of that installed base is still concentrated in high-volume hospital centers, so there's a long runway into smaller accounts.
JORDAN: Beyond CAS, Cardiac Rhythm Management grew 15%, Cranial & Spinal Technologies grew 13%, and Surgical — their biggest unit at over $6 billion a year — grew 9%. Pelvic health jumped 15%, largely thanks to Altaviva, where procedures doubled sequentially.
ALEX: Now let's talk strategy, because Medtronic made two acquisition-adjacent announcements the same morning as earnings. First, a $700 million strategic investment and distribution deal with Cornerstone Robotics for their Sentire surgical robot, outside the U.S.
JORDAN: This one got some pointed questions on the call. One analyst basically asked, "Does this mean you've lost confidence in Hugo, your own robot?" And Martha pushed back hard — said it's the opposite. Hugo's on track to hit 50,000 procedures by year-end, growing at twice the market rate. Cornerstone is about extending reach into international markets where Hugo isn't the right fit, not replacing it.
ALEX: Basically building a multi-platform robotics portfolio instead of betting everything on one system.
JORDAN: Exactly — and Thierry noted the financial impact this year is minimal, mostly just some foregone interest on that investment, but they expect real revenue and margin lift starting in fiscal 2028.
ALEX: The second deal was Pi-Cardia, in structural heart — first FDA-cleared technology for leaflet modification in TAVR procedures for patients at risk of coronary obstruction. That's part of a broader doubling-down in structural heart, alongside their earlier investment in Anteris.
JORDAN: On guidance, they ra
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione